

# Mona O Mohsen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8861504/publications.pdf>

Version: 2024-02-01

40  
papers

1,885  
citations

361045

20  
h-index

329751

37  
g-index

50  
all docs

50  
docs citations

50  
times ranked

2247  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Major findings and recent advances in virus-like particle (VLP)-based vaccines. <i>Seminars in Immunology</i> , 2017, 34, 123-132.   | 2.7 | 375       |
| 2  | Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines. <i>Annals of Medicine</i> , 2022, 54, 524-540.   | 1.5 | 225       |
| 3  | On Iron Metabolism and Its Regulation. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4591.  | 1.8 | 141       |
| 4  | Harnessing Nanoparticles for Immunomodulation and Vaccines. <i>Vaccines</i> , 2017, 5, 6.  | 2.1 | 113       |
| 5  | Interaction of Viral Capsid-Derived Virus-Like Particles (VLPs) with the Innate Immune System. <i>Vaccines</i> , 2018, 6, 37.  | 2.1 | 113       |
| 6  | Virus-like particles for vaccination against cancer. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2020, 12, e1579.   | 3.3 | 74        |
| 7  | Delivering adjuvants and antigens in separate nanoparticles eliminates the need of physical linkage for effective vaccination. <i>Journal of Controlled Release</i> , 2017, 251, 92-100.   | 4.8 | 69        |
| 8  | In vitro data suggest that Indian delta variant B.1.617 of SARS-CoV-2 escapes neutralization by both receptor affinity and immune evasion. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 111-117.                          | 2.7 | 69        |
| 9  | The 3Ds in virus-like particle based vaccines: Design, Delivery and Dynamics. <i>Immunological Reviews</i> , 2020, 296, 155-168.   | 2.8 | 57        |
| 10 | SARS-CoV-2 structural features may explain limited neutralizing-antibody responses. <i>Npj Vaccines</i> , 2021, 6, 2.  | 2.9 | 48        |
| 11 | Vaccination with nanoparticles combined with micro-adjuvants protects against cancer. , 2019, 7, 114.  |     | 41        |
| 12 | Targeting Mutated Plus Germline Epitopes Confers Pre-clinical Efficacy of an Instantly Formulated Cancer Nano-Vaccine. <i>Frontiers in Immunology</i> , 2019, 10, 1015.  | 2.2 | 39        |
| 13 | Virus-like particles (VLP) in prophylaxis and immunotherapy of allergic diseases. <i>Allergo Journal International</i> , 2018, 27, 245-255.  | 0.9 | 38        |
| 14 | A scalable and highly immunogenic virus-like particle-based vaccine against SARS-CoV-2. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 243-257.   | 2.7 | 35        |
| 15 | Zika Virus-Derived E-DIII Protein Displayed on Immunologically Optimized VLPs Induces Neutralizing Antibodies without Causing Enhancement of Dengue Virus Infection. <i>Vaccines</i> , 2019, 7, 72.  | 2.1 | 33        |
| 16 | Development of a Vaccine against SARS-CoV-2 Based on the Receptor-Binding Domain Displayed on Virus-Like Particles. <i>Vaccines</i> , 2021, 9, 395.  | 2.1 | 32        |
| 17 | New 3-Cyano-2-Substituted Pyridines Induce Apoptosis in MCF 7 Breast Cancer Cells. <i>Molecules</i> , 2016, 21, 230.   | 1.7 | 30        |
| 18 | BNT162b2 mRNA COVID-19 vaccine induces antibodies of broader cross-reactivity than natural infection, but recognition of mutant viruses is up to 10-fold reduced. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 2895-2998. | 2.7 | 29        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Virus-Like Particle (VLP) Plus Microcrystalline Tyrosine (MCT) Adjuvants Enhance Vaccine Efficacy Improving T and B Cell Immunogenicity and Protection against Plasmodium berghei/vivax. <i>Vaccines</i> , 2017, 5, 10.  | 2.1 | 28        |
| 20 | The impact of size on particle drainage dynamics and antibody response. <i>Journal of Controlled Release</i> , 2021, 331, 296-308.   | 4.8 | 27        |
| 21 | Molecular definition of severe acute respiratory syndrome coronavirus 2 receptor-binding domain mutations: Receptor affinity versus neutralization of receptor interaction. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 143-149. | 2.7 | 26        |
| 22 | AP205 VLPs Based on Dimerized Capsid Proteins Accommodate RBM Domain of SARS-CoV-2 and Serve as an Attractive Vaccine Candidate. <i>Vaccines</i> , 2021, 9, 403.   | 2.1 | 25        |
| 23 | Vaccination against Allergy: A Paradigm Shift?. <i>Trends in Molecular Medicine</i> , 2020, 26, 357-368.   | 3.5 | 24        |
| 24 | Microcrystalline Tyrosine (MCT <sup>®</sup> ): A Depot Adjuvant in Licensed Allergy Immunotherapy Offers New Opportunities in Malaria. <i>Vaccines</i> , 2017, 5, 32.  | 2.1 | 15        |
| 25 | Bedside formulation of a personalized multi-neoantigen vaccine against mammary carcinoma. , 2022, 10, e002927.   |     | 14        |
| 26 | Intranasal administration of a virus like particles-based vaccine induces neutralizing antibodies against SARS-CoV-2 and variants of concern. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2446-2458.                             | 2.7 | 14        |
| 27 | Shaping Modern Vaccines: Adjuvant Systems Using MicroCrystalline Tyrosine (MCT <sup>®</sup> ). <i>Frontiers in Immunology</i> , 2020, 11, 594911.  | 2.2 | 12        |
| 28 | Neutralization of MERS coronavirus through a scalable nanoparticle vaccine. <i>Npj Vaccines</i> , 2021, 6, 107.  | 2.9 | 12        |
| 29 | TLR7 Signaling Shapes and Maintains Antibody Diversity Upon Virus-Like Particle Immunization. <i>Frontiers in Immunology</i> , 2021, 12, 827256.   | 2.2 | 11        |
| 30 | Increased Receptor Affinity and Reduced Recognition by Specific Antibodies Contribute to Immune Escape of SARS-CoV-2 Variant Omicron. <i>Vaccines</i> , 2022, 10, 743.   | 2.1 | 11        |
| 31 | Early Transcriptional Signature in Dendritic Cells and the Induction of Protective T Cell Responses Upon Immunization With VLPs Containing TLR Ligands—A Role for CCL2. <i>Frontiers in Immunology</i> , 2019, 10, 1679.   | 2.2 | 10        |
| 32 | A Novel Double Mosaic Virus-like Particle-Based Vaccine against SARS-CoV-2 Incorporates Both Receptor Binding Motif (RBM) and Fusion Domain. <i>Vaccines</i> , 2021, 9, 1287.  | 2.1 | 10        |
| 33 | Culpability, blame, and stigma after pregnancy loss in Qatar. <i>BMC Pregnancy and Childbirth</i> , 2019, 19, 215.   | 0.9 | 9         |
| 34 | Virus-Like Particles Are Efficient Tools for Boosting mRNA-Induced Antibodies. <i>Frontiers in Immunology</i> , 0, 13, .   | 2.2 | 8         |
| 35 | DOPS Adjuvant Confers Enhanced Protection against Malaria for VLP-TRAP Based Vaccines. <i>Diseases (Basel, Switzerland)</i> , 2018, 6, 107.  | 1.0 | 7         |
| 36 | Murine CD8 T-cell functional avidity is stable in vivo but not in vitro: Independence from homologous prime/boost time interval and antigen density. <i>European Journal of Immunology</i> , 2020, 50, 505-514.  | 1.6 | 6         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 37 | Anti-IAPP Monoclonal Antibody Improves Clinical Symptoms in a Mouse Model of Type 2 Diabetes. <i>Vaccines</i> , 2021, 9, 1316.                                | 2.1 | 6         |
| 38 | Increased receptor affinity of SARS-CoV-2: a new immune escape mechanism. <i>Npj Vaccines</i> , 2022, 7, .  | 2.9 | 6         |
| 39 | Induction of Broadly Cross-Reactive Antibodies by Displaying Receptor Binding Domains of SARS-CoV-2 on Virus-like Particles. <i>Vaccines</i> , 2022, 10, 307. | 2.1 | 4         |
| 40 | Cover Image, Volume 12, Issue 1. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2020, 12, e1610.                                | 3.3 | 0         |